Description: IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson's; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.
Home Page: www.irlab.se
Arvid Wallgrens Backe 20
Gothenburg,
413 46
Sweden
Phone:
46 3 17 57 38 00
Officers
| Name | Title |
|---|---|
| Dr. Kristina Torfgard Ph.D. | Chief Executive Officer |
| Mr. Viktor Siewertz | Chief Financial Officer |
| Dr. Clas Sonesson Ph.D. | Chief Scientific Officer |
| Dr. Peder Svensson Ph.D. | Chief Information Officer and Director of Computational Chemistry & Biology |
| Ms. Tove Bergenholt | Global IR & Communications |
| Ms. Cecilia Tivert Stenberg B.Sc, B.Sc. | Head of Finance & Human Resource and Director of Accounting & Human Resources |
| Dr. Nicholas Waters Ph.D. | Executive VP and Head of R&D |
| Dr. Joakim Tedroff M.D., Ph.D. | Chief Medical Officer |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 23.3645 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 17.049 |
| Price-to-Sales TTM: | 12.8093 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 32 |